ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market on its Lupuzor™ programme in patients with systemic lupus erythematosus (“SLE”) Key highlights: In conjunction with its partner Avion Pharmaceuticals (“Avion”), ImmuPharma confirms that a Phase 2/3 adaptive trial will be the best design for the next clinical study…

Notification of major holdings Click here

NOTIFICATION OF MAJOR HOLDINGS Click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non Executive Directors) has determined to award  Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows: Tim…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market. Review of 2022 and Outlook for 2023 As we approach the end of 2022 the Company can confirm that it continues to work proactively, together with our partner Avion Pharmaceuticals (“Avion) and external advisors, on the preparations around the…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to update the market on a recent meeting in Atlanta, USA with our US partner, Avion Pharmaceuticals, LLC (“Avion”) for strategic discussions around ImmuPharma’s Lupuzor™ clinical program. This included Avion continuing its support to the clinical program of Lupuzor™ for Lupus, as well…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update on Lupuzor™, following the Company’s recent announcement on 14 September 2022, that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. In summary, the FDA…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2022 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Loss for the Period of £1.7m (30 June 2021:  £3.7m)…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that, further to the Company’s notification of 7 July 2022, its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. The FDA response was detailed and included significant…

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 3,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £150,000. New Ordinary Shares and Admission The New Ordinary Shares…

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announced  on 7 July 2022 that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had advised that it had received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). It was announced at that time that : the statement of…

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 2,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £100,000. New Ordinary Shares and Admission The New Ordinary Shares…

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 1,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £50,000. New Ordinary Shares and Admission The New Ordinary Shares…

TR-1: Standard form for notification of major holdings To download click here

ImmuPharma plc (“ImmuPharma” or “the Company”), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM. Consequently, the Company’s issued share capital…

ImmuPharma plc (“ImmuPharma” or “the Company”), announces that it has raised £0.95 million (before expenses) pursuant to a Broker Option following the announcement made on 3 August 2022. Under the terms of a placing agreement entered into by the Company with Stanford Capital Partners Limited (“SCP”) and SPARK Advisory Partners Limited on 3 August, the…

ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin, COO, will provide a live investor presentation via the Investor Meet Company platform today, 4 August 2022 at 12:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until…

Related Party Transactions ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a subscription and a placing to raise c£1.1 million (the “Subscription” and “Placing”) through the issue of 21,818,182 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 5 pence…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners (“SCP”) has today initiated research coverage on the Company. The full text of the report can be accessed via SCP’s website: www.stanfordcp.co.uk/research/ and via Research Tree. Investors are required to self-certify and register in order to access…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. ImmuPharma’s Chairman & CEO, Tim McCarthy said: “We are delighted to have had such overwhelming support from right across…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that, having met all the Food and Drug Administration’s (“FDA”) requirements, Avion Pharmaceuticals (“Avion”), its US partner, has confirmed that it has sought final regulatory guidance from the FDA, as it actively prepares for the start of the international Phase 3…